Pharma Pulse: Big Medicine Breakups and the Tariff Scramble
In today’s Pharma Pulse, bipartisan lawmakers target PBM vertical integration, while pharma giants race to secure tariff-exempt pricing deals.
2m Feb 13
2m
Pharma Pulse: A Regulatory Standoff for mRNA Flu Shots and the Dual Power of GLP-1s
In today’s Pharma Pulse, the FDA issues a rare “Refusal-to-File" for Moderna’s influenza vaccine, while new research confirms GLP-1s act as potent tools against chronic inflammation.
2m Feb 12
2m
Pharma Pulse: The Provider Debate and Takeda’s $1.7 Billion AI Bet
In today’s Pharma Pulse, the American College of Physicians issues a formal rejection of the term "provider," while Takeda partners with Iambic Therapeutics to accelerate small-molecule discovery through AI.
2m Feb 11
2m
Pharma Pulse: The GLP-1 Copycat Crackdown and the 340B Rebate Retreat
In today’s Pharma Pulse, a telehealth giant retreats from the weight loss pill conflict, while safety-net hospitals secure a major legal victory against 340B reform.
2m Feb 10
2m
Pharma Pulse: TrumpRx Takes Flight and Novo Nordisk’s Super Bowl Gambit
In today’s Pharma Pulse, TrumpRx officially goes live, while Novo Nordisk prepares to take the oral version of Wegovy to the biggest stage in advertising.
1m Feb 09
1m
Pharma Pulse: PBM Reform Hits the Courtroom and Telehealth’s Legislative Victory
In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides long-term certainty for the digital health revolution.
2m Feb 06
2m
Pharma Pulse: Transparency Mandates and the Novartis Patent Storm
In today’s Pharma Pulse, the biopharma landscape enters a transformative phase as the US signs landmark PBM reforms into law, while Novartis braces for the largest patent expiration cycle in its history.
2m Feb 05
2m
Pharma Pulse: AstraZeneca’s US Setback and Europe’s Medicine Marathon
In today’s Pharma Pulse, AstraZeneca faces a complete response letter for its self-injectable lupus drug, while the EMA gives the green light to a historic wave of new therapies for MASH, rare diseases, and postmenopause.
2m Feb 04
2m
Pharma Pulse: Onshoring the Supply Chain
In today’s Pharma Pulse, the FDA launches its "PreCheck" pilot to speed up domestic factory approvals, while new SELECT trial data shows that semaglutide significantly slashes hospital admission rates.
2m Feb 03
2m
Pharma Pulse: The Access Gap
In today’s Pharma Pulse, a new national survey exposes the depth of America’s prescription access crisis, while AstraZeneca and Eli Lilly commit billions of dollars to next-generation weight-loss therapies and domestic manufacturing.
2m Feb 02
2m
Pharma Pulse: HHS Bypasses PBMs and the Reality of GLP-1 Weight Regain
In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant weight regain after stopping tirzepatide and semaglutide.
2m Jan 30
2m
Pharma Pulse: AI’s $120M Cardiometabolic Play
In today’s Pharma Pulse, the AAP defies federal vaccine cuts, Morris & Dickson scales its specialty footprint, and Insilico Medicine targets cardiometabolic health with a new partnership.
2m Jan 29
2m
Pharma Pulse: Climate Risks to the Supply Chain
In today’s Pharma Pulse, extreme weather tests the resilience of community pharmacies, while CMS proposes a near-flat 0.09% update for Medicare Advantage and Part D payments in 2027.
2m Jan 28
2m
Pharma Pulse: Manufacturing Front-Loading and the Smart Speaker Intervention
In today’s Pharma Pulse, global pharmaceutical production hits a surge as manufacturers brace for US tariff shifts, while a new study reveals how smart speakers are slashing A1C levels for older adults.
2m Jan 26
2m
Pharma Pulse: US Exits the World Health Organization; Hospitals Overwhelmed by Historic Flu Crisis
In today’s Pharma Pulse, the United States finalizes its departure from global health oversight, while domestic providers face a record-breaking surge in respiratory hospitalizations.
1m Jan 23
1m
Pharma Pulse: Federal Funding Averts Shutdown and Pfizer’s Adjuvant Play
In today’s Pharma Pulse, Congress races to secure funding, while Novavax nets a half-billion-dollar validation of its non-aluminum vaccine technology.
2m Jan 22
2m
Pharma Pulse: Industry Backlash, GSK’s $2.2B Immunology Bet, and the Future of Wearables
In today’s Pharma Pulse, over 200 health groups denounce childhood vaccine schedule cuts, GSK acquires RAPT Therapeutics, and BD partners with ten23 health to scale large-volume injectors.
2m Jan 21
2m
Pharma Pulse: Global AI Alignment, the TrumpRx Pivot, and Nano-Delivery GLP-1s
In today’s Pharma Pulse, the FDA and EMA synchronize on AI standards, a potential divide in pricing strategy occurs, and BoomRx launches a needle-free nanoemulsion for weight loss.
2m Jan 20
2m
Pharma Pulse: Novartis Warns of Trade Fragmentation; Hospital M&A Hits Record Low; Copay Shock Warning
In today’s Pharma Pulse, Novartis calls for a shift from "cost-containment" to structural reform, hospital mergers hit their lowest point in 15 years, and new data warns of "cost shocks" driven by copay accumulators.
2m Jan 19
2m
Pharma Pulse: Trump’s New Healthcare Roadmap, FDA Vaccine Warnings, and BPD to Lead The Agency Network
In today’s Pharma Pulse, President Trump unveils a patient payment plan, the FDA flags a rare seizure risk for several leading flu vaccines, and MJH Life Sciences expands its data-driven reach.
2m Jan 16
2m
Pharma Pulse: Navigating the New Era of Healthcare
In today’s Pharma Pulse, AbbVie joins TrumpRx, shingles vaccines reveal a longevity boost, and HER2 therapies break new ground in cancer treatment.
2m Jan 15
2m
Pharma Pulse: Precision Cancer Care
In today’s Pharma Pulse, Novartis expands its US radioligand footprint, and 15,000 New York City nurses go on strike.
2m Jan 14
2m
Pharma Pulse: Amazon Pharmacy Sells Oral Wegovy, J&J’s Billion-Dollar Hub, and the Debt-Housing Crisis
In today’s Pharma Pulse, Amazon Pharmacy launches Novo's first oral Wegovy pill with transparent cash pricing, Johnson & Johnson triples down on North Carolina manufacturing, and new clinical data links medical debt to rising eviction risks.
2m Jan 13
2m
Pharma Pulse: J&J Enters TrumpRx and the Red Flags in Pediatric Vaccines
In today’s Pharma Pulse, Johnson & Johnson secures a major tariff deal by joining the federal drug discount portal, while new data warns that missing early infant shots is the leading predictor of skipped MMR vaccines.
2m Jan 12
2m
Pharma Pulse: Merger Fever, Lilly’s $1.2B Inflammatory Bet, and the Birth of CareTria
In today’s Pharma Pulse, healthcare leaders brace for a surge in dealmaking, Eli Lilly secures a suite of oral NLRP3 inhibitors, and Knipper Health rebrands to streamline the path from order to therapy.
2m Jan 09
2m
Pharma Pulse: FDA Fast-Tracks Merck Blockbusters, GSK’s Precision Data Bet, and DHL’s Massive PA Hub
In today’s Pharma Pulse, the FDA issues two high-stakes priority vouchers for cholesterol and cancer therapies, GSK leverages genomic data to refine drug targets, and DHL completes a one-million-square-foot logistics center of excellence.
2m Jan 08
2m
Pharma Pulse: Pediatric Vaccine Revisions, COPD Mortality Trends, and Eli Lilly’s $1.3B Obesity Deal
In today’s Pharma Pulse, federal officials slash the childhood immunization schedule, new data underscores the life-saving impact of COVID vaccines for COPD patients, and Eli Lilly targets the AMPK pathway in a massive new oral obesity collaboration.
2m Jan 07
2m
Pharma Pulse: GoodRx Rollout for Oral Wegovy; Major Reprieve for 340B Hospitals; Sanofi’s $2.5B AI Bet
In today’s Pharma Pulse, GoodRx slashes cash prices for the new Wegovy pill, a federal judge halts the 340B rebate pilot, and Sanofi doubles down on Earendil Labs’ AI platform for autoimmune breakthroughs.
3m Jan 06
3m
Pharma Pulse: FDA Ends 40-Year Drought for Motion Sickness
In today’s Pharma Pulse, Vanda Pharmaceuticals secures landmark approval for Nereus, while Hoth Therapeutics files dual patents to tackle treatment-induced skin toxicities.
2m Jan 05
2m
Pharma Pulse: A Win for Bone Health
In today’s Pharma Pulse, the FDA clears new denosumab biosimilars for osteoporosis and cancer-related bone loss, while healthcare leaders grapple with a surge in "nuclear verdicts" driven by shifting public sentiment.
2m Jan 02
2m
Pharma Pulse: FDA Clears First Oral Wegovy; Yusen Logistics Seals European Health Deal
In today’s Pharma Pulse, Novo Nordisk secures a landmark approval for a weight-loss pill, while Yusen Logistics expands its end-to-end supply chain capabilities across Europe.
2m Dec 24, 2025
2m
Pharma Pulse: US Manufacturing Expansion, Oncology Partnerships, and Workplace Health
In today’s Pharma Pulse, Samsung Biologics enters the US market with a $280 million site acquisition, AstraZeneca secures a multi-billion-dollar cancer deal, and new research identifies occupational drivers of long COVID.
3m Dec 23, 2025
3m
Pharma Pulse: TrumpRx Gains Nine New Pharma Partners; DHL Expands LAX Cold Chain Hub
In today’s Pharma Pulse, major pharma players commit to most-favored-nation pricing, as DHL bolsters West Coast logistics for temperature-sensitive drugs.
2m Dec 22, 2025
2m
Pharma Pulse: Navigating the Biosecure Act, Post-Viral Sleep Phenotypes, and Rising Insurance Costs
In today’s Pharma Pulse, the Senate advances legislation to block "biotechnology companies of concern," clinical research ties COVID-19 to REM-dominant sleep apnea, and a new analysis reveals an affordability breaking point for employer-sponsored health insurance.
2m Dec 19, 2025
2m
Pharma Pulse: The ACA Subsidy Cliff and New Frontiers for GLP-1s
In today’s Pharma Pulse, House Republicans block a critical insurance subsidy extension, as new research highlights the oncology benefits of GLP-1s.
2m Dec 18, 2025
2m
Pharma Pulse: Onshoring Investments and the AI Frontier
In today’s Pharma Pulse, Novartis and Moderna anchor a domestic manufacturing surge, while AI-driven biomarker discovery and physician well-being reshape the future of clinical care.
3m Dec 17, 2025
3m
Pharma Pulse: SOBI’s $1.5B Gout Acquisition Clears Pipeline; New Cholesterol Drug Lerochol Scores on Convenience
In today’s Pharma Pulse, SOBI strengthens its gout franchise by acquiring Arthrosi Therapeutics for up to $1.5 billion, securing the Phase III asset pozdeutinurad, and much more.
3m Dec 16, 2025
3m
Pharma Pulse: Amgen's Uplizna Secures CD19 Approval for Myasthenia Gravis, as Asthma Biologic Switches Highlight Efficacy Expectations Gap
In today’s Pharma Pulse, the FDA approves Amgen’s Uplizna (inebilizumab-cdon), the first CD19-targeted therapy for gMG with convenient twice-yearly dosing, and much more.
2m Dec 15, 2025
2m
Pharma Pulse: ACA Subsidy Gridlock Spurs Cost Crisis, as Lilly’s Retatrutide Delivers Positive Results in Phase III Trial
In today’s Pharma Pulse, the Senate fails to advance bills extending enhanced ACA subsidies, leaving 22 million enrollees facing sharp premium increases, and much more.
2m Dec 12, 2025
2m
Pharma Pulse: FDA Fast-Tracks Antibiotic Approval, as Protected EHR Time Combats Physician Burnout
In today’s Pharma Pulse, Augmentin XR is the first drug approved under the FDA's new CNPV pilot program and much more.
2m Dec 11, 2025
2m
Pharma Pulse: FDA Shifts CAR-T Standards and Maryland Expands Medical Class Size, as Pharma Channels Brace for Massive Patent Cliff Disruption
In today’s Pharma Pulse, the University of Maryland expands its medical class to combat physician shortages and much more.
2m Dec 10, 2025
2m
Pharma Pulse: Lilly’s Jaypirca Challenges Imbruvica, as AI Chatbots Could Prove Key to Boosting Vaccine Rates
In today’s Pharma Pulse, new trials confirm AI chatbots are a successful and sustainable tool for increasing pneumococcal vaccine uptake among older adults and much more.
3m Dec 09, 2025
3m
Pharma Pulse: ACIP Ends Universal Hep B Birth Dose
In today’s Pharma Pulse, the ACIP votes to end the decades-long universal hepatitis B birth dose recommendation; meanwhile, former FDA commissioners warn that new vaccine policies are compromising the long-standing regulatory framework and jeopardizing public health security.
2m Dec 08, 2025
2m
Pharma Pulse: New CDER Director Appointed, as Medicaid Shows Potential to Save Cancer Lives
In today’s Pharma Pulse, Dr. Tracy Beth Høeg is named acting CDER director amidst high leadership turnover, promising modernization and transparency.
2m Dec 05, 2025
2m
Pharma Pulse: Pazdur Retires from FDA, While Public Trusts AMA Over CDC on Vaccines, and New Data Redefines Adherence as an Emotional Crisis
In today’s Pharma Pulse, Dr. Richard Pazdur retires from his CDER director role weeks after his appointment, and much more.
3m Dec 04, 2025
3m
Pharma Pulse: Long COVID Exercise Win, $150M Gene Editing Play, and Compounding Pharmacy Expansions
In today’s Pharma Pulse, a structured exercise program is proven to manage persistent long COVID symptoms, while Regeneron commits $150 million upfront to Tessera for a gene writing therapy targeting AATD, and Strive Pharmacy invests in a massive Arizona facility to boost national personalized medicine capacity.
2m Dec 03, 2025
2m
Pharma Pulse: US-UK Trade Deal Forces Pricing Shift, as Lilly Deepens GLP-1 Price Cuts and RSV-Asthma Link Confirmed
In today’s Pharma Pulse, a US-UK trade agreement mandates that the UK’s NICE agency raises its QALY threshold, increasing access to innovative drugs, and much more.
2m Dec 02, 2025
2m
Pharma Pulse: Medicare Price Cuts and Vaccine Wins
From billions in drug savings and more, we present to you today’s Pharma Pulse.
2m Dec 01, 2025
2m
Pharma Pulse: Medicare Price Negotiations Heat Up, as FDA Approves SMA Gene Therapy
In today’s Pharma Pulse, the federal government prepares to unveil newly negotiated Medicare prices for 15 high-cost drugs, while Novartis receives FDA approval for Itvisma, a one-time gene therapy offering a new treatment pathway for older children and adults with spinal muscular atrophy.
3m Nov 26, 2025
3m
Pharma Pulse: RSV Protection Wanes, AstraZeneca Invests Big, and Novo Nordisk Faces Pipeline Setback
A new Pharma Pulse unpacks declining RSV vaccine durability in older adults, AstraZeneca’s $2 billion expansion of its US biologics manufacturing footprint, and the stock-shaking Phase III struggle affecting Novo Nordisk’s Alzheimer’s ambitions.
3m Nov 25, 2025
3m